EMEA (Europe, Middle East and Africa) Fragile X Syndrome Market Report 2017

December 2017 | 112 pages | ID: E9C2D813132EN
QYResearch

Abstracts

In this report, the EMEA Fragile X Syndrome market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Fragile X Syndrome for these regions, from 2012 to 2022 (forecast)

• Europe: Germany, France, UK, Russia, Italy and Benelux;
• Middle East: Saudi Arabia, Israel, UAE and Iran;
• Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Fragile X Syndrome market competition by top manufacturers/players, with Fragile X Syndrome sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including

• Aelis Farma SAS
• Alcobra Ltd
• AMO Pharma Limited
• Confluence Pharmaceuticals LLC
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Marinus Pharmaceuticals, Inc.
• MI.TO. Technology S.r.L.
• Neuren Pharmaceuticals Limited
• Ovid Therapeutics Inc.
• Sage Therapeutics, Inc.
• Zynerba Pharmaceuticals, Inc.

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

• ACT-01
• AMO-01
• ANAVEX-273
• AUT-00206
• Bryostatin-1
• Cannabidiol
• Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Clinic
• Hopital
• Research Center

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

EMEA (Europe, Middle East and Africa) Fragile X Syndrome Market Report 2017

1 FRAGILE X SYNDROME OVERVIEW

1.1 Product Overview and Scope of Fragile X Syndrome
1.2 Classification of Fragile X Syndrome
  1.2.1 EMEA Fragile X Syndrome Market Size (Sales) Comparison by Type (2012-2022)
  1.2.2 EMEA Fragile X Syndrome Market Size (Sales) Market Share by Type (Product Category) in 2016
  1.2.3 ACT-01
  1.2.4 AMO-01
  1.2.5 ANAVEX-273
  1.2.6 AUT-00206
  1.2.7 Bryostatin-1
  1.2.8 Cannabidiol
  1.2.9 Others
1.3 EMEA Fragile X Syndrome Market by Application/End Users
  1.3.1 EMEA Fragile X Syndrome Sales (Volume) and Market Share Comparison by Application (2012-2022
  1.3.2 Clinic
  1.3.3 Hopital
  1.3.4 Research Center
1.4 EMEA Fragile X Syndrome Market by Region
  1.4.1 EMEA Fragile X Syndrome Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 Europe Status and Prospect (2012-2022)
  1.4.3 Middle East Status and Prospect (2012-2022)
  1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of Fragile X Syndrome (2012-2022)
  1.5.1 EMEA Fragile X Syndrome Sales and Growth Rate (2012-2022)
  1.5.2 EMEA Fragile X Syndrome Revenue and Growth Rate (2012-2022)

2 EMEA FRAGILE X SYNDROME COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA Fragile X Syndrome Market Competition by Players/Manufacturers
  2.1.1 EMEA Fragile X Syndrome Sales Volume and Market Share of Major Players (2012-2017)
  2.1.2 EMEA Fragile X Syndrome Revenue and Share by Players (2012-2017)
  2.1.3 EMEA Fragile X Syndrome Sale Price by Players (2012-2017)
2.2 EMEA Fragile X Syndrome (Volume and Value) by Type/Product Category
  2.2.1 EMEA Fragile X Syndrome Sales and Market Share by Type (2012-2017)
  2.2.2 EMEA Fragile X Syndrome Revenue and Market Share by Type (2012-2017)
  2.2.3 EMEA Fragile X Syndrome Sale Price by Type (2012-2017)
2.3 EMEA Fragile X Syndrome (Volume) by Application
2.4 EMEA Fragile X Syndrome (Volume and Value) by Region
  2.4.1 EMEA Fragile X Syndrome Sales and Market Share by Region (2012-2017)
  2.4.2 EMEA Fragile X Syndrome Revenue and Market Share by Region (2012-2017)
  2.4.3 EMEA Fragile X Syndrome Sales Price by Region (2012-2017)

3 EUROPE FRAGILE X SYNDROME (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe Fragile X Syndrome Sales and Value (2012-2017)
  3.1.1 Europe Fragile X Syndrome Sales Volume and Growth Rate (2012-2017)
  3.1.2 Europe Fragile X Syndrome Revenue and Growth Rate (2012-2017)
3.2 Europe Fragile X Syndrome Sales and Market Share by Type
3.3 Europe Fragile X Syndrome Sales and Market Share by Application
3.4 Europe Fragile X Syndrome Sales Volume and Value (Revenue) by Countries
  3.4.1 Europe Fragile X Syndrome Sales Volume by Countries (2012-2017)
  3.4.2 Europe Fragile X Syndrome Revenue by Countries (2012-2017)
  3.4.3 Germany Fragile X Syndrome Sales and Growth Rate (2012-2017)
  3.4.4 France Fragile X Syndrome Sales and Growth Rate (2012-2017)
  3.4.5 UK Fragile X Syndrome Sales and Growth Rate (2012-2017)
  3.4.6 Russia Fragile X Syndrome Sales and Growth Rate (2012-2017)
  3.4.7 Italy Fragile X Syndrome Sales and Growth Rate (2012-2017)
  3.4.8 Benelux Fragile X Syndrome Sales and Growth Rate (2012-2017)

4 MIDDLE EAST FRAGILE X SYNDROME (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East Fragile X Syndrome Sales and Value (2012-2017)
  4.1.1 Middle East Fragile X Syndrome Sales Volume and Growth Rate (2012-2017)
  4.1.2 Middle East Fragile X Syndrome Revenue and Growth Rate (2012-2017)
4.2 Middle East Fragile X Syndrome Sales and Market Share by Type
4.3 Middle East Fragile X Syndrome Sales and Market Share by Application
4.4 Middle East Fragile X Syndrome Sales Volume and Value (Revenue) by Countries
  4.4.1 Middle East Fragile X Syndrome Sales Volume by Countries (2012-2017)
  4.4.2 Middle East Fragile X Syndrome Revenue by Countries (2012-2017)
  4.4.3 Saudi Arabia Fragile X Syndrome Sales and Growth Rate (2012-2017)
  4.4.4 Israel Fragile X Syndrome Sales and Growth Rate (2012-2017)
  4.4.5 UAE Fragile X Syndrome Sales and Growth Rate (2012-2017)
  4.4.6 Iran Fragile X Syndrome Sales and Growth Rate (2012-2017)

5 AFRICA FRAGILE X SYNDROME (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa Fragile X Syndrome Sales and Value (2012-2017)
  5.1.1 Africa Fragile X Syndrome Sales Volume and Growth Rate (2012-2017)
  5.1.2 Africa Fragile X Syndrome Revenue and Growth Rate (2012-2017)
5.2 Africa Fragile X Syndrome Sales and Market Share by Type
5.3 Africa Fragile X Syndrome Sales and Market Share by Application
5.4 Africa Fragile X Syndrome Sales Volume and Value (Revenue) by Countries
  5.4.1 Africa Fragile X Syndrome Sales Volume by Countries (2012-2017)
  5.4.2 Africa Fragile X Syndrome Revenue by Countries (2012-2017)
  5.4.3 South Africa Fragile X Syndrome Sales and Growth Rate (2012-2017)
  5.4.4 Nigeria Fragile X Syndrome Sales and Growth Rate (2012-2017)
  5.4.5 Egypt Fragile X Syndrome Sales and Growth Rate (2012-2017)
  5.4.6 Algeria Fragile X Syndrome Sales and Growth Rate (2012-2017)

6 EMEA FRAGILE X SYNDROME MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 Aelis Farma SAS
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Fragile X Syndrome Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Aelis Farma SAS Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Alcobra Ltd
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Fragile X Syndrome Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Alcobra Ltd Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 AMO Pharma Limited
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Fragile X Syndrome Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 AMO Pharma Limited Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Confluence Pharmaceuticals LLC
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Fragile X Syndrome Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Confluence Pharmaceuticals LLC Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Eli Lilly and Company
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Fragile X Syndrome Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Eli Lilly and Company Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 F. Hoffmann-La Roche Ltd.
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Fragile X Syndrome Product Type, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 F. Hoffmann-La Roche Ltd. Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Marinus Pharmaceuticals, Inc.
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Fragile X Syndrome Product Type, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Marinus Pharmaceuticals, Inc. Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 MI.TO. Technology S.r.L.
  6.8.1 Company Basic Information, Manufacturing Base and Competitors
  6.8.2 Fragile X Syndrome Product Type, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 MI.TO. Technology S.r.L. Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Neuren Pharmaceuticals Limited
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 Fragile X Syndrome Product Type, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Neuren Pharmaceuticals Limited Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Ovid Therapeutics Inc.
  6.10.1 Company Basic Information, Manufacturing Base and Competitors
  6.10.2 Fragile X Syndrome Product Type, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Ovid Therapeutics Inc. Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Sage Therapeutics, Inc.
6.12 Zynerba Pharmaceuticals, Inc.

7 FRAGILE X SYNDROME MANUFACTURING COST ANALYSIS

7.1 Fragile X Syndrome Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Fragile X Syndrome

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Fragile X Syndrome Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Fragile X Syndrome Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA FRAGILE X SYNDROME MARKET FORECAST (2017-2022)

11.1 EMEA Fragile X Syndrome Sales, Revenue and Price Forecast (2017-2022)
  11.1.1 EMEA Fragile X Syndrome Sales and Growth Rate Forecast (2017-2022)
  11.1.2 EMEA Fragile X Syndrome Revenue and Growth Rate Forecast (2017-2022)
  11.1.3 EMEA Fragile X Syndrome Price and Trend Forecast (2017-2022)
11.2 EMEA Fragile X Syndrome Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe Fragile X Syndrome Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt Fragile X Syndrome Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa Fragile X Syndrome Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA Fragile X Syndrome Sales Forecast by Type (2017-2022)
11.7 EMEA Fragile X Syndrome Sales Forecast by Application (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Fragile X Syndrome
Figure EMEA Fragile X Syndrome Sales Volume (K Pcs) by Type (2012-2022)
Figure EMEA Fragile X Syndrome Sales Volume Market Share by Type (Product Category) in 2016
Figure ACT-01 Product Picture
Figure AMO-01 Product Picture
Figure ANAVEX-273 Product Picture
Figure AUT-00206 Product Picture
Figure Bryostatin-1 Product Picture
Figure Cannabidiol Product Picture
Figure Others Product Picture
Figure EMEA Fragile X Syndrome Sales Volume (K Pcs) by Application (2012-2022)
Figure EMEA Sales Market Share of Fragile X Syndrome by Application in 2016
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Hopital Examples
Table Key Downstream Customer in Hopital
Figure Research Center Examples
Table Key Downstream Customer in Research Center
Figure EMEA Fragile X Syndrome Market Size (Million USD) by Region (2012-2022)
Figure Europe Fragile X Syndrome Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe Fragile X Syndrome Revenue (Million USD) Status and Forecast by Countries
Figure Middle East Fragile X Syndrome Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East Fragile X Syndrome Revenue (Million USD) Status and Forecast by Countries
Figure Africa Fragile X Syndrome Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa Fragile X Syndrome Revenue (Million USD) Status and Forecast by Countries
Figure EMEA Fragile X Syndrome Sales Volume and Growth Rate (2012-2022)
Figure EMEA Fragile X Syndrome Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA Fragile X Syndrome Market Major Players Product Sales Volume (K Pcs) (2012-2017)
Table EMEA Fragile X Syndrome Sales Volume (K Pcs) of Major Players (2012-2017)
Table EMEA Fragile X Syndrome Sales Share by Players (2012-2017)
Figure 2016 Fragile X Syndrome Sales Share by Players
Figure 2017 Fragile X Syndrome Sales Share by Players
Figure EMEA Fragile X Syndrome Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA Fragile X Syndrome Revenue (Million USD) by Players (2012-2017)
Table EMEA Fragile X Syndrome Revenue Share by Players (2012-2017)
Table 2016 EMEA Fragile X Syndrome Revenue Share by Players
Table 2017 EMEA Fragile X Syndrome Revenue Share by Players
Table EMEA Fragile X Syndrome Sale Price (USD/Pcs) by Players (2012-2017)
Table EMEA Fragile X Syndrome Sales (K Pcs) and Market Share by Type (2012-2017)
Table EMEA Fragile X Syndrome Sales Share by Type (2012-2017)
Figure Sales Market Share of Fragile X Syndrome by Type (2012-2017)
Figure EMEA Fragile X Syndrome Sales Market Share by Type (2012-2017)
Table EMEA Fragile X Syndrome Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA Fragile X Syndrome Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Fragile X Syndrome by Type in 2016
Table EMEA Fragile X Syndrome Sale Price (USD/Pcs) by Type (2012-2017)
Table EMEA Fragile X Syndrome Sales (K Pcs) and Market Share by Application (2012-2017)
Table EMEA Fragile X Syndrome Sales Share by Application (2012-2017)
Figure Sales Market Share of Fragile X Syndrome by Application (2012-2017)
Figure EMEA Fragile X Syndrome Sales Market Share by Application in 2016
Table EMEA Fragile X Syndrome Sales (K Pcs) and Market Share by Region (2012-2017)
Table EMEA Fragile X Syndrome Sales Share by Region (2012-2017)
Figure Sales Market Share of Fragile X Syndrome by Region (2012-2017)
Figure EMEA Fragile X Syndrome Sales Market Share in 2016
Table EMEA Fragile X Syndrome Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA Fragile X Syndrome Revenue Share by Region (2012-2017)
Figure Revenue Market Share of Fragile X Syndrome by Region (2012-2017)
Figure EMEA Fragile X Syndrome Revenue Market Share Regions in 2016
Table EMEA Fragile X Syndrome Sales Price (USD/Pcs) by Region (2012-2017)
Figure Europe Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure Europe Fragile X Syndrome Revenue and Growth Rate (2012-2017)
Table Europe Fragile X Syndrome Sales (K Pcs) by Type (2012-2017)
Table Europe Fragile X Syndrome Market Share by Type (2012-2017)
Figure Europe Fragile X Syndrome Market Share by Type in 2016
Table Europe Fragile X Syndrome Sales (K Pcs) by Application (2012-2017)
Table Europe Fragile X Syndrome Market Share by Application (2012-2017)
Figure Europe Fragile X Syndrome Market Share by Application in 2016
Table Europe Fragile X Syndrome Sales (K Pcs) by Countries (2012-2017)
Table Europe Fragile X Syndrome Sales Market Share by Countries (2012-2017)
Figure Europe Fragile X Syndrome Sales Market Share by Countries (2012-2017)
Figure Europe Fragile X Syndrome Sales Market Share by Countries in 2016
Table Europe Fragile X Syndrome Revenue (Million USD) by Countries (2012-2017)
Table Europe Fragile X Syndrome Revenue Market Share by Countries (2012-2017)
Figure Europe Fragile X Syndrome Revenue Market Share by Countries (2012-2017)
Figure Europe Fragile X Syndrome Revenue Market Share by Countries in 2016
Figure Germany Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure France Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure UK Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure Russia Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure Italy Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure Benelux Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure Middle East Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure Middle East Fragile X Syndrome Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East Fragile X Syndrome Sales (K Pcs) by Type (2012-2017)
Table Middle East Fragile X Syndrome Market Share by Type (2012-2017)
Figure Middle East Fragile X Syndrome Market Share by Type (2012-2017)
Table Middle East Fragile X Syndrome Sales (K Pcs) by Applications (2012-2017)
Table Middle East Fragile X Syndrome Market Share by Applications (2012-2017)
Figure Middle East Fragile X Syndrome Sales Market Share by Application in 2016
Table Middle East Fragile X Syndrome Sales Volume (K Pcs) by Countries (2012-2017)
Table Middle East Fragile X Syndrome Sales Volume Market Share by Countries (2012-2017)
Figure Middle East Fragile X Syndrome Sales Volume Market Share by Countries in 2016
Table Middle East Fragile X Syndrome Revenue (Million USD) by Countries (2012-2017)
Table Middle East Fragile X Syndrome Revenue Market Share by Countries (2012-2017)
Figure Middle East Fragile X Syndrome Revenue Market Share by Countries (2012-2017)
Figure Middle East Fragile X Syndrome Revenue Market Share by Countries in 2016
Figure Saudi Arabia Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure Israel Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure UAE Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure Iran Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure Africa Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure Africa Fragile X Syndrome Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa Fragile X Syndrome Sales (K Pcs) by Type (2012-2017)
Table Africa Fragile X Syndrome Sales Market Share by Type (2012-2017)
Figure Africa Fragile X Syndrome Sales Market Share by Type (2012-2017)
Figure Africa Fragile X Syndrome Sales Market Share by Type in 2016
Table Africa Fragile X Syndrome Sales (K Pcs) by Application (2012-2017)
Table Africa Fragile X Syndrome Sales Market Share by Application (2012-2017)
Figure Africa Fragile X Syndrome Sales Market Share by Application (2012-2017)
Table Africa Fragile X Syndrome Sales Volume (K Pcs) by Countries (2012-2017)
Table Africa Fragile X Syndrome Sales Market Share by Countries (2012-2017)
Figure Africa Fragile X Syndrome Sales Market Share by Countries (2012-2017)
Figure Africa Fragile X Syndrome Sales Market Share by Countries in 2016
Table Africa Fragile X Syndrome Revenue (Million USD) by Countries (2012-2017)
Table Africa Fragile X Syndrome Revenue Market Share by Countries (2012-2017)
Figure Africa Fragile X Syndrome Revenue Market Share by Countries (2012-2017)
Figure Africa Fragile X Syndrome Revenue Market Share by Countries in 2016
Figure South Africa Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure Nigeria Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure Egypt Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure Algeria Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Table Aelis Farma SAS Fragile X Syndrome Basic Information List
Table Aelis Farma SAS Fragile X Syndrome Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Aelis Farma SAS Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure Aelis Farma SAS Fragile X Syndrome Sales Market Share in EMEA (2012-2017)
Figure Aelis Farma SAS Fragile X Syndrome Revenue Market Share in EMEA (2012-2017)
Table Alcobra Ltd Fragile X Syndrome Basic Information List
Table Alcobra Ltd Fragile X Syndrome Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Alcobra Ltd Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure Alcobra Ltd Fragile X Syndrome Sales Market Share in EMEA (2012-2017)
Figure Alcobra Ltd Fragile X Syndrome Revenue Market Share in EMEA (2012-2017)
Table AMO Pharma Limited Fragile X Syndrome Basic Information List
Table AMO Pharma Limited Fragile X Syndrome Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure AMO Pharma Limited Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure AMO Pharma Limited Fragile X Syndrome Sales Market Share in EMEA (2012-2017)
Figure AMO Pharma Limited Fragile X Syndrome Revenue Market Share in EMEA (2012-2017)
Table Confluence Pharmaceuticals LLC Fragile X Syndrome Basic Information List
Table Confluence Pharmaceuticals LLC Fragile X Syndrome Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Confluence Pharmaceuticals LLC Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure Confluence Pharmaceuticals LLC Fragile X Syndrome Sales Market Share in EMEA (2012-2017)
Figure Confluence Pharmaceuticals LLC Fragile X Syndrome Revenue Market Share in EMEA (2012-2017)
Table Eli Lilly and Company Fragile X Syndrome Basic Information List
Table Eli Lilly and Company Fragile X Syndrome Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Eli Lilly and Company Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure Eli Lilly and Company Fragile X Syndrome Sales Market Share in EMEA (2012-2017)
Figure Eli Lilly and Company Fragile X Syndrome Revenue Market Share in EMEA (2012-2017)
Table F. Hoffmann-La Roche Ltd. Fragile X Syndrome Basic Information List
Table F. Hoffmann-La Roche Ltd. Fragile X Syndrome Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure F. Hoffmann-La Roche Ltd. Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure F. Hoffmann-La Roche Ltd. Fragile X Syndrome Sales Market Share in EMEA (2012-2017)
Figure F. Hoffmann-La Roche Ltd. Fragile X Syndrome Revenue Market Share in EMEA (2012-2017)
Table Marinus Pharmaceuticals, Inc. Fragile X Syndrome Basic Information List
Table Marinus Pharmaceuticals, Inc. Fragile X Syndrome Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Marinus Pharmaceuticals, Inc. Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure Marinus Pharmaceuticals, Inc. Fragile X Syndrome Sales Market Share in EMEA (2012-2017)
Figure Marinus Pharmaceuticals, Inc. Fragile X Syndrome Revenue Market Share in EMEA (2012-2017)
Table MI.TO. Technology S.r.L. Fragile X Syndrome Basic Information List
Table MI.TO. Technology S.r.L. Fragile X Syndrome Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure MI.TO. Technology S.r.L. Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure MI.TO. Technology S.r.L. Fragile X Syndrome Sales Market Share in EMEA (2012-2017)
Figure MI.TO. Technology S.r.L. Fragile X Syndrome Revenue Market Share in EMEA (2012-2017)
Table Neuren Pharmaceuticals Limited Fragile X Syndrome Basic Information List
Table Neuren Pharmaceuticals Limited Fragile X Syndrome Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Neuren Pharmaceuticals Limited Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure Neuren Pharmaceuticals Limited Fragile X Syndrome Sales Market Share in EMEA (2012-2017)
Figure Neuren Pharmaceuticals Limited Fragile X Syndrome Revenue Market Share in EMEA (2012-2017)
Table Ovid Therapeutics Inc. Fragile X Syndrome Basic Information List
Table Ovid Therapeutics Inc. Fragile X Syndrome Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Ovid Therapeutics Inc. Fragile X Syndrome Sales (K Pcs) and Growth Rate (2012-2017)
Figure Ovid Therapeutics Inc. Fragile X Syndrome Sales Market Share in EMEA (2012-2017)
Figure Ovid Therapeutics Inc. Fragile X Syndrome Revenue Market Share in EMEA (2012-2017)
Table Sage Therapeutics, Inc. Fragile X Syndrome Basic Information List
Table Zynerba Pharmaceuticals, Inc. Fragile X Syndrome Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Fragile X Syndrome
Figure Manufacturing Process Analysis of Fragile X Syndrome
Figure Fragile X Syndrome Industrial Chain Analysis
Table Raw Materials Sources of Fragile X Syndrome Major Manufacturers in 2016
Table Major Buyers of Fragile X Syndrome
Table Distributors/Traders List
Figure EMEA Fragile X Syndrome Sales (K Pcs) and Growth Rate Forecast (2017-2022)
Figure EMEA Fragile X Syndrome Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA Fragile X Syndrome Price (USD/Pcs) and Trend Forecast (2017-2022)
Table EMEA Fragile X Syndrome Sales (K Pcs) Forecast by Region (2017-2022)
Figure EMEA Fragile X Syndrome Sales Market Share Forecast by Region (2017-2022)
Table EMEA Fragile X Syndrome Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA Fragile X Syndrome Revenue Market Share Forecast by Region (2017-2022)
Table Europe Fragile X Syndrome Sales (K Pcs) Forecast by Countries (2017-2022)
Figure Europe Fragile X Syndrome Sales Market Share Forecast by Countries (2017-2022)
Table Europe Fragile X Syndrome Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe Fragile X Syndrome Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East Fragile X Syndrome Sales (K Pcs) Forecast by Countries (2017-2022)
Figure Middle East Fragile X Syndrome Sales Market Share Forecast by Countries (2017-2022)
Table Middle East Fragile X Syndrome Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East Fragile X Syndrome Revenue Market Share Forecast by Countries (2017-2022)
Table Africa Fragile X Syndrome Sales (K Pcs) Forecast by Countries (2017-2022)
Figure Africa Fragile X Syndrome Sales Market Share Forecast by Countries (2017-2022)
Table Africa Fragile X Syndrome Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa Fragile X Syndrome Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA Fragile X Syndrome Sales (K Pcs) Forecast by Type (2017-2022)
Figure EMEA Fragile X Syndrome Sales Market Share Forecast by Type (2017-2022)
Table EMEA Fragile X Syndrome Sales (K Pcs) Forecast by Application (2017-2022)
Figure EMEA Fragile X Syndrome Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources